Сравнение
Oxytocin vs. Pasireotid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
50-56-6
396091-73-9
Молекулярная масса
1007.19 g/mol
1047.21 g/mol
Период полувыведения
0.05 h
нет данных
Последовательность
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2нет данных
Механизм действия
Oxytocin
Oxytocin is synthesised in the hypothalamus and released via the posterior pituitary. Peripherally it binds the oxytocin receptor, a G-protein-coupled receptor, and through the phospholipase-C cascade and calcium release triggers contraction of uterine smooth muscle and milk ejection — the pharmacological basis of the obstetric approval. Centrally, oxytocin acts as a neuromodulator and has been linked to social bonding, trust and modulation of stress and anxiety circuits. Its central effects in humans are mechanistically incompletely understood, particularly because it is unclear to what extent peripherally or intranasally administered oxytocin crosses the blood-brain barrier.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
1
из них на людях
4
1
Зафиксированные эффекты
3
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
0
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Oxytocin and Pasireotid?
- Oxytocin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Oxytocin: Oxytocin is an endogenous nonapeptide hormone of the posterior pituitary. In synthetic form (Pitocin, Syntocinon) it has been approved for decades to induce and augment labour and to control postpartum uterine bleeding. Strictly separate from this is intranasal use to influence social behaviour, trust, anxiety or autism symptoms: this use is unapproved, purely experimental, and yields inconsistent and often negative results in controlled trials. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Oxytocin or Pasireotid?
- The highest available evidence level is "РКИ на людях" for Oxytocin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Oxytocin and Pasireotid in Germany and the United States?
- Германия: Oxytocin — Рецептурный, Pasireotid — Рецептурный. США: Oxytocin — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.